Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » Maxygen Signs Research Agreement with NCI, Files For Second Stock Offering

Maxygen Signs Research Agreement with NCI, Files For Second Stock Offering

Mar 09, 2000
Premium

R

EDWOOD CITY, Calif.--Maxygen announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute for pharmaceutical protein development. In the three-year deal, the company will apply its MolecularBreed-ing directed evolution technologies to the development of novel protein pharmaceuticals for cancer treatments. NCI will provide expertise in characterizing and evaluating the proteins for therapeutic potential. The specific target proteins and indications were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Millions of Tests

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Court Pick and Science

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Arthur Ashkin Dies

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

PNAS Papers on Alzheimer's Transcriptomes, Bladder Cancer Mutations, CRC Drivers

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

What's Popular?

In Informatics

  1. Sema4, Janssen Partner on Patient Identification for Cancer Clinical Trials

  2. Catalog DNA Merges Molecular Biology, Information Theory to Pursue DNA-Based Computing

    Premium

  3. Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

  4. M2Gen Expands Partnership With Discovery Life Sciences

  5. Center for Genomic Regulation's COVID-19 Viral Beacon Digs Into Thousands of SARS-CoV-2 Genomes

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.